Shares of Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG – Get Free Report) have received a consensus rating of “Moderate Buy” from the five analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $41.75.
Several equities research analysts recently issued reports on the company. Jefferies Financial Group assumed coverage on Hemab Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $39.00 price target for the company. Zacks Research upgraded Hemab Therapeutics to a “hold” rating in a research note on Wednesday. Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th. Evercore assumed coverage on Hemab Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $50.00 price target for the company. Finally, Wedbush assumed coverage on Hemab Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $42.00 price target for the company.
View Our Latest Report on Hemab Therapeutics
Hemab Therapeutics Stock Performance
Hemab Therapeutics (NASDAQ:COAG – Get Free Report) last issued its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.
Insiders Place Their Bets
In other Hemab Therapeutics news, major shareholder Ra Capital Management, L.P. bought 3,802 shares of the business’s stock in a transaction on Tuesday, May 19th. The stock was purchased at an average cost of $24.97 per share, for a total transaction of $94,935.94. Following the completion of the purchase, the insider directly owned 6,375,972 shares of the company’s stock, valued at approximately $159,208,020.84. This trade represents a 0.06% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders acquired 2,902,872 shares of company stock worth $53,769,784 in the last three months.
About Hemab Therapeutics
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.
Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.
Featured Articles
- Five stocks we like better than Hemab Therapeutics
- Meta’s Manus Mess: Why China Blocked the Deal and What It Means
- China Deal Ignites Boeing’s Financial Afterburners
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
Receive News & Ratings for Hemab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
